• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Duke William E. covered exercise/tax liability with 4,503 shares, decreasing direct ownership by 15% to 26,182 units

    12/19/22 5:09:34 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials
    Get the next $BCAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Duke William E.

    (Last) (First) (Middle)
    C/O APEXIGEN, INC.
    75 SHOREWAY ROAD, SUITE C

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Apexigen, Inc. [ APGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    12/15/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/15/2022 F 4,503(1) D $1.06 26,182 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.
    Remarks:
    /s/ Francis Sarena, by power of attorney 12/19/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Wong Amy covered exercise/tax liability with 2,851 shares, decreasing direct ownership by 17% to 13,637 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:57:25 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Sarena Francis Willard covered exercise/tax liability with 6,916 shares, decreasing direct ownership by 17% to 33,084 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:49:39 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Hsu Frank J. covered exercise/tax liability with 4,323 shares, decreasing direct ownership by 17% to 20,677 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:41:54 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    SEC Filings

    View All

    SEC Form 10-Q filed by Brookline Capital Acquisition Corp.

    10-Q - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 5:13:36 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Brookline Capital Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Other Events, Financial Statements and Exhibits

    8-K - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 4:07:21 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form S-8 filed by Brookline Capital Acquisition Corp.

    S-8 - Apexigen, Inc. (0001814140) (Filer)

    10/6/22 7:58:36 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apexigen to Participate in the Brookline Capital Markets Newport Symposium

    SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st

    7/11/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Leadership Updates

    Live Leadership Updates

    View All

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Financials

    Live finance-specific insights

    View All

    Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

    - Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022

    3/18/22 6:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Apexigen, Inc. (0001814140) (Subject)

    8/8/22 12:18:48 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Brookline Capital Acquisition Corp. (Amendment)

    SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    8/1/22 3:48:29 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    4/13/22 3:32:08 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials